Insmed Inc (INSM)vsNeuraxis, Inc. (NRXS)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NRXS
Neuraxis, Inc.
$7.51
+6.52%
HEALTHCARE · Cap: $81.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 17936% more annual revenue ($606.42M vs $3.36M). INSM leads profitability with a -2.1% profit margin vs -2.2%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NRXS
Avoid20
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Revenue surging 21.7% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 32.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NRXS
The strongest argument for NRXS centers on Debt/Equity, Revenue Growth. Revenue growth of 21.7% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NRXS
The primary concerns for NRXS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NRXS is a growth play — different risk/reward profiles.
NRXS carries more volatility with a beta of 2.49 — expect wider price swings.
NRXS is growing revenue faster at 21.7% — sustainability is the question.
NRXS generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 20/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Neuraxis, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?